{"url_path":"/sec/halo/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000068-index.html","accession_number":"0001159036-26-000068","cik":"0001159036","ticker":"HALO","issuer_name":"HALOZYME THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000068-index.html","primary_entity_key":"0001159036","primary_entity_name":"HALOZYME THERAPEUTICS, INC."},"word_count":102,"has_tables":true,"body_markdown":"Item 5.Other Information\n\nDuring the three months ended March 31, 2026, the following director adopted a Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.\n\nTrading Arrangement\n\nName and Title\n\nAction\n\nDate\n\nRule 10b5-1*\n\nNon-Rule 10b5-1**\n\nTotal Shares To Be Sold\n\nExpiration Date\n\nMahesh Krishnan\n\nAdoption\n3/19/2026\nX\n7,3046/1/2027\n\nDirector\n\n*    Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.\n\n** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act\n\n65\n\n[Table of Contents](#i66ba8166e9c94bfbbdc8e24cab8d4507_7)"}